Gianluca Trifiró is an MD with an MSc in clinical epidemiology, a post-graduation degree in clinical pharmacology and a PhD in pharmacoepidemiology. He is currently working as an assistant professor at both the Erasmus University Medical Center in Rotterdam, The Netherlands and the University of Messina in Italy.

In recent years, his main research activities have focused on the scientific coordination and management of multicentre, national and international multi-database studies (i.e. EU-ADR, ARITMO, SAFEGUARD, MPI-AGE). These assessed post-marketing drug use and safety using multiple European electronic medical record databases.

He is a member of the Sicilian regional committee on biosimilar use, a member of the scientific secretariat of the pharmacovigilance office of the Italian Drug Agency, and an external consultant for the Italian College of General Practitioners focusing on the conduct of pharmacoepidemiology studies using the GP nationwide-database.

Since 2007, he is a referee for research grants funded by the European Commission (FP7 and Horizon 2020 program).

He has authored more than 100 peer-reviewed scientific publications in international journals and is an editor and reviewer for several international journals in the area of pharmacovigilance and pharmacoepidemiology.

Pauline Guyon

Pauline Guyon is a project manager for Fair Park II. In this position, she is in charge of running the project in close collaboration with the coordinator (Prof David Devos) and oversees its implementation. She also provides advice and support to the members of the project and she leads the consortium with the assistance of colleagues at Inserm-Transfert. She previously worked for five years as legal counsel for the research activities of Lille University Hospital. During this period she gained clinical trial expertise in terms of writing and editing trial protocols through to the completion of clinical trials.

Dominique Deplanque is both a neurologist and professor of medical pharmacology at Lille 2 University and Lille University Hospital. For more than ten years he has been involved in the management of clinical research activities. Moreover he is head of the Clinical Investigation Center (CIC 1403 Inserm-Lille University Hospital), a center fully dedicated to clinical research. He is also head of the Clinical Research Federation, a structure that is managing all the clinical research projects sponsored by Lille University Hospital.

David Devos obtained his Doctor of Neurology and Doctor of Neuroscience degrees from the University of Lille, Lille, France. Between 2002 and 2010, he worked as a hospital physician in the Department of Neurology, University hospital of Lille, where he is now a Professor in Medical Pharmacology. He is coordinating the neurogenetic center of Lille (Spinocerebellar ataxia, spastic paraplegia, Neurodegeneration with Brain Iron Accumulation). He is consultant and running research at the expert center of Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS) of Lille. He is co-coordinating the French network of PD (NS-Park-F-CRIN) and of ALS (ACT4ALS). His main research interests are preclinical and clinical studies of disease-modifying strategies in neurodegenerative disease and particularly PD and ALS for which he received several prices including the European Pharmacology Scientific Award EACPT. He participated in 30 studies including 14 multicenter trials and 14 as Coordinator (10 in progress), 4 European Commission funded projects (H2020) including 2 in neurosciences (iron, ferroptotic cell death), 1 large European clinical trial FAIRPARK-2 and 1 on diagnosis on Covid-19. He published about 200 publications. He obtained 6 patents leading to 3 industrial transfers for which he launched and cofounded 3 Start up (InBrain Pharma for Brain Infusion, InVenis Biotherapies for platelet-based biotherapies and CorDial-IT for diagnosis tools).